Avience Biomedicals IPO Details
The Avience Biomedicals IPO is a book build issue with a total issue size of ₹30 cr, comprising of fresh issue of 1371600 equity shares. Avience Biomedicals IPO opened for subscription on Jun 18, 2026 and closed on Jun 22, 2026. Avience Biomedicals IPO is set price band at ₹196 to ₹208 per share, with a lot size of 600 shares. Minimum investment for Retail investors was ₹249,600.00 (at the upper price band) to apply for one lot.
The basis of allotment got finalized on Jun 23, 2026, and listed on the NSE on Jun 25, 2026.
Skyline Financial Services Private Ltd has been appointed as the registrar. Fintellectual Corporate Advisors Private Limited are the Book Running Lead Manager for the issue.
Before investing in the Avience Biomedicals IPO, investors should review the company's financial performance, business objectives, and risk factors mentioned in the offer documents and apply before the subscription window closes.
- Price Band
- ₹ 196 – 208
- Lot Size
- 600
- Issue Size
- ₹30 Cr
- Minimum Investment
- ₹249600 (1200 Shares)
- Listing Date
- 25 June 2026
Current GMP
₹145 (+69.71%)
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
About Avience Biomedicals Limited
Incorporated in June 2024, Avience Biomedicals Limited is an ISO-certified company engaged in the manufacturing, supply, export, distribution, and trading of advanced molecular diagnostic solutions. The company operates in the fields of biotechnology, genomics, and the In-Vitro Diagnostics (IVD) industry, serving a wide range of healthcare and research institutions.
The company has significantly expanded its product portfolio from IVD rapid test kits to a comprehensive range of diagnostic and medical devices. Its offerings cater primarily to the B2B (Business-to-Business) and B2G (Business-to-Government) segments, reflecting its commitment to addressing diverse healthcare and diagnostic requirements.
Avience Biomedicals Limited serves Pathology Laboratories, Microbiology Laboratories, Hospitals, Diagnostic Centers, Research Institutions, and Government Healthcare Organizations across India and international markets.
The company’s state-of-the-art manufacturing facility is located in Noida, Uttar Pradesh, enabling efficient production and quality control of its healthcare products.
Product Portfolio
1. Rapid Diagnostic Test Kits
- AVISURE Dengue Combo Test
- Malaria Rapid Test (Pf/Pv)
- AVISURE Syphilis Rapid Test
- Other infectious disease diagnostic kits
2. Biochemistry Analyzers and Reagents
- BS-240 Fully Automatic Biochemistry Analyzer
- AVIENBIO Albumin Kit
- Various clinical chemistry reagents and consumables
3. Molecular Diagnostic Solutions
- COVID-19 Hid RT-qPCR Assay
- Molecular testing kits for infectious disease detection
- Advanced genomics and PCR-based diagnostic products
4. Hematology Analyzers
- BC-20s 3-Part Hematology Analyzer
- Hematology testing systems and related consumables
5. Medical Devices
- Oxy-5 Oxygen Concentrator
- Oxy-10 Oxygen Concentrator
- Viral Transport Medium (VTM)
- Other healthcare and diagnostic equipment
In addition to its manufacturing operations, the company actively engages in the distribution and trading of medical equipment and diagnostic devices, strengthening its presence across the healthcare value chain.
Human Resources
As of January 31, 2026, Avience Biomedicals Limited employed 75 permanent employees and 33 contractual employees, reflecting its growing operational capabilities and commitment to supporting its expanding business activities.
With a focus on quality, innovation, and customer-centric healthcare solutions, Avience Biomedicals Limited continues to strengthen its position in the biotechnology, diagnostics, and medical devices sectors, both in India and international markets.
Avience Biomedicals IPO Promoters
- Mr. Dharam Deo Choudhary
- Mr. Ram Nagina Choudhary
- Mr. Janardan Pal
- Ms. Deepa Choudhary
Promoters Holding
Holding Pre Issue
87.89%
Holding Post Issue
64.59%
Avience Biomedicals IPO Objective
The Company Avience Biomedicals IPO proposes to utilise the Net Proceeds from the Issue towards the following objects.
- Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh.
- Funding the working capital requirement of our Company
- General Corporate Purpose
Address / Contact Info
Avience Biomedicals Ltd.
C-11, Block-C,Community Centre,
Janakpuri A-3,Delhi, New Delhi, 110058
Phone: 1800-12-04-636
Email: info@avienbio.com
Website: https://avienbio.com/
IPO Snapshot
Book Running Lead Managers
- Fintellectual Corporate Advisors Private Limited
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
Avience Biomedicals IPO is a Book-building IPO with a total issue size of ₹30 crore. The Avience Biomedicals IPO price band is ₹196 to 208 per share. The Avience Biomedicals IPO subscription opens on Thu, Jun 18, 2026, and closes on Mon, Jun 22, 2026. The Avience Biomedicals IPO will be listed on the NSE. Skyline Financial Services Private Ltd is the registrar for the Avience Biomedicals IPO.
The Avience Biomedicals IPO opens on Thu, Jun 18, 2026 and closes on Mon, Jun 22, 2026
Avience Biomedicals IPO Price Band is ₹196 to 208 per share.
Avience Biomedicals IPO lot size is 600 shares, Retail investors need a minimum investment of ₹249600 based on the upper price band
The minimum investment for Avience Biomedicals IPO is ₹249600, based on one lot of 600 shares at the upper price band of ₹208 per share.
Investors can apply for the Avience Biomedicals IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Mon, Jun 22, 2026. The application amount remains blocked until the Avience Biomedicals IPO allotment is finalized.
Avience Biomedicals IPO issue size is ₹30 crores.
Avience Biomedicals IPO allotment date is Wed, Jul 1, 2026.
The registrar for Avience Biomedicals IPO is Skyline Financial Services Private Ltd. Investors can go to Skyline Financial Services Private Ltd website to check Avience Biomedicals IPO allotment status, refund processing, and other IPO-related information.
The Avience Biomedicals IPO GMP (Grey Market Premium) is ₹145 as of Thu, Jun 25, 2026. Based on the upper price band of ₹208 per share, the estimated Avience Biomedicals IPO listing price is ₹353, indicating a potential listing gain of approximately 0% over the issue price.